NCT05321849 is a clinical trial of Echocardiography guide in Echocardiography, sponsored by National Cardiovascular Center Harapan Kita Hospital Indonesia.

Who is sponsoring NCT05321849?

NCT05321849 is sponsored by National Cardiovascular Center Harapan Kita Hospital Indonesia.

What drugs are being tested in NCT05321849?

Interventions in NCT05321849: Echocardiography guide.

What condition does NCT05321849 study?

NCT05321849 studies Echocardiography, PDA.

Is NCT05321849 still recruiting?

NCT05321849 is currently completed. Last updated 11 April 2022.

Last reviewed 2022-04-11 · How we verify

NCT05321849

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Echocardiography-guided Percutaneous Patent Ductus Arteriosus Closure

Completed Last updated 11 April 2022

What this trial tests

trial testing Echocardiography guide in Echocardiography in 60 participants. Completed in 23 June 2020.

Timeline

12 March 2019

Primary endpoint
23 June 2020

23 June 2020

Quick facts

Lead sponsor	National Cardiovascular Center Harapan Kita Hospital Indonesia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	60
Start date	12 March 2019
Primary completion	23 June 2020
Estimated completion	23 June 2020
Sites	1 location across Indonesia

Drugs / interventions tested

Echocardiography guide

Conditions studied

Echocardiography — all drugs for Echocardiography →
PDA — all drugs for PDA →

Sponsor

National Cardiovascular Center Harapan Kita Hospital Indonesia

Who can join

Adults 0 to 18, any sex, with Echocardiography or PDA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since the first successful percutaneous closure under transoesophageal echocardiographic (TEE) guidance, many centres explored transcatheter procedures without fluoroscopy. This single centre study aims to show the feasibility and safety of percutaneous patent ductus arteriosus (PDA) closure under echocardiography-only guidance during our one-year experience. Patients with PDA were recruited for percutaneous PDA closure guided by either fluoroscopy or echocardiography-only in National Cardiovascular Center Harapan Kita. Patients were evaluated clinically and radiologically using TTE at 6, 24 and 48 hours after the procedure. Primary endpoint was the procedural success. Secondary endpoints were the procedural time and the rate of adverse events. Echocardiography-guided PDA closure is non-inferior to fluoroscopy-guided PDA closure, with similar procedural times. However, this method is operator-dependent and requires an experienced team for it to be performed successfully.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Echocardiography-Guided Percutaneous Patent Ductus Arteriosus Closure: 1-Year Single Center Experience in Indonesia.
Siagian SN, Prakoso R, Putra BE, Kurniawati Y, et al · · 2022 · cited 11× · PMID 35677684 · DOI 10.3389/fcvm.2022.885140

Verify or expand the search:

Other recruiting trials for Echocardiography

Currently open trials in the same condition.

NCT07390903 — GLS in Difficult CPB Weaning · recruiting
NCT07133516 — A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography · recruiting
NCT07042893 — Effects of Pulmonary Resection on Right Ventricular Function · recruiting
NCT07030062 — Echocardiography Guided TAVR (Echo TAVR) · recruiting
NCT06860997 — Clinical Echocardiography and S' Wave for Early Recognition of Acute Coronary Syndrome in the Emergency Department, A Pr · NA · recruiting

Other National Cardiovascular Center Harapan Kita Hospital Indonesia trials

Trials by the same sponsor.

NCT06091982 — Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury · completed
NCT05579964 — The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot · Phase 2, PHASE3 · completed
NCT06766045 — Comparison of Ultrasound with Fluoroscopy to Assess Diaphragmatic Paralysis After Congenital Heart Disease Surgery · NA · completed
NCT05622292 — The Effectivity of the Mobile App "HARKIT I-Care" in Secondary Prevention in Post-ACS Patients · NA · unknown
NCT05300802 — The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Card · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05321849 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cardiovascular Center Harapan Kita Hospital Indonesia
Last refreshed: 11 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05321849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing